We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 284

IP in the life sciences industries 2013

  • Intellectual Asset Management magazine
  • -
  • Canada, Germany, India, Mexico, Sweden, USA
  • -
  • May 24 2013

No matter what stage of the business cycle they have reached, it is critical for companies in the life sciences sector to identify, protect and

Universities abroad experiment with no-fee licensing to drive biotech partnerships

  • Shook Hardy & Bacon LLP
  • -
  • Australia, Canada, European Union, United Kingdom, USA
  • -
  • May 16 2013

Universities in Australia, Canada, Europe, and the United Kingdom have reportedly embraced a 2010 Glasgow University initiative under which companies

Data protection: defining innovative drug in Canada

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • April 22 2013

Canada amended its Data Protection Regulations in 2006 to provide protection for innovative drugs in a second attempt to implement Canada's 1994

Leave to appeal to the Court of Appeal Re: motion to strike pleadings granted in respect of claims to unjust enrichment, denied in respect of claims under the Trade-Marks Act

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 6 2013

In this case, Apotex has sued Eli Lilly for damages pursuant to s. 8 of the Patented Medicines (Notice of Compliance) Regulations. Eli Lilly brought a

BLG Monthly Update

  • Borden Ladner Gervais LLP
  • -
  • Argentina, Australia, Canada, United Kingdom, USA
  • -
  • December 19 2012

The BLG Monthly Update is a digest of recent developments in the law which Neil Guthrie, our National Director of Research, thinks you will find

Industry news

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • July 2 2012

Bill C-11, The Copyright Modernization Act has received Royal Assent

Other industry news

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • April 2 2012

As we mentioned last week, CIPO is consulting on practice respecting inventive concept, statutory subject matter, diagnostic methods and medical uses

Appeal dismissed regarding motion granting leave to amend pleadings

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • March 12 2012

The Federal Court of Appeal (FCA) upheld a decision of the Motions Judge, which upheld the decision of a Prothonotary, granting leave to the respondents to amend their pleadings

CETA trade negotiations 2011 drug market exclusivity in the EU and Canada

  • Norton Rose Fulbright LLP
  • -
  • Canada, European Union
  • -
  • October 21 2011

A consideration of why Canada should answer the European Union’s call for heightened IP protection for pharmaceuticals

Production of product and manufacturing information denied

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • August 10 2011

This is an appeal of a decision of a Prothonotary, refusing to order Mylan to produce requested information about its manufacturing process and the crystal structure of efavirenz in its product